Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancer

• Pyxis Oncology highlighted MICVO, a first-in-concept extracellular-targeting antibody-drug conjugate aimed at EDB+ fibronectin in tumor matrix.
• Phase 1 dose escalation dosed 80 patients across 18 sites, testing 0.3-8 mg/kg every three weeks.
• Responses emerged from 3.6 mg/kg; 3.6-5.4 mg/kg became the focus range for continued development.
• In R/M HNSCC dose escalation, confirmed ORR was 50% with 100% disease control at 3.6 and 5.4 mg/kg.
• 5.4 mg/kg was selected for dose expansion; multiple clinical data catalysts are expected in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.